Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Schematic depicting the involvement of regional sympathetic nerves in the mediation of pain in early-stage TMJ-OA. GA, UNITED STATES, Febru ...

Via a collaboration with Nasa, Auxilium has installed a 3D printer on the ISS to test the promise of manufacturing in microgravity.

Peripheral neuropathy: a condition that can cause tingling, numbness, and pain in the extremities, especially the feet and ...

In 2004, a research group at Peking University First Hospital discovered a mutation in the gene coding for a sodium-channel ...

On the cold morning of January 31, 2006, Nitin Narain, a 25-year-old Delhi native, began experiencing unusual fatigue, ...

“We are pleased to welcome Jesse to the Axogen team," said Michael Dale, Chief Executive Officer, and Director, Axogen. "His extensive experience in regulatory strategy and deep understanding of the ...

Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain, while reducing the effects ...

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

It is important to add pain management to leprosy treatment protocols. This can reduce the challenges that patients face. Read on.

Maharashtra reports 149 suspected Guillain-Barré cases, with 124 confirmed. Five fatalities have occurred, including a 36-year-old man and a 60-year-old man. Currently, 28 patients require ventilator ...